FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2517435317> ?p ?o ?g. }

• W2517435317 endingPage "215" @default.
• W2517435317 startingPage "206" @default.
• W2517435317 abstract "Anaplastic large cell lymphoma (ALCL), anaplastic lymphoma kinase (ALK)-negative (ALCL-ALK−) is a provisional entity in the WHO 2008 Classification that represents 2–3% of NHL and 12% of T-cell NHL. No particular risk factor has been clearly identified for ALCL, but a recent study showed an odds ratio of 18 for ALCL associated with breast implants. Usually, the architecture of involved organs is eroded by solid, cohesive sheets of neoplastic cells, with peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) and classical Hodgkin lymphoma being the main differential diagnoses. In this regard, staining for PAX5 and CD30 is useful. Translocations involving ALK are absent, TCR genes are clonally rearranged. CGH and GEP studies suggest a tendency of ALCL-ALK− to differ both from PTCL-NOS and from ALCL-ALK+. Patients with ALCL-ALK− are usually adults with a median age of 54–61 years, and a male-to-female ratio of 0.9. At presentation, ALCL-ALK− is often in III–IV stage, with B symptoms, high International Prognostic Index score, high lactate dehydrogenase serum levels, and an aggressive course. ALCL-ALK− presents with lymph node involvement in ∼50% of cases; extranodal spread (20%) is less common. Staging work-up for ALCL-ALK− is similar to that routinely used for nodal NHL. Overall prognosis is poor, with a 5-year OS of 30–49%, which is significantly worse when compared to OS reported in patients with ALCL-ALK+ (5-year: 70–86%). Patients with systemic ALCL exhibit a significantly better survival compared with patients with PTCL-NOS, with a 5-year OS of 51% and 32%, respectively. Age, PIT scoring system, β2-microglobulin, and bone marrow infiltration are the main prognostic factors. The expression of proteins involved in the regulation of apoptosis (caspase 3, Bcl-2, PI9) and of CD56 is related to clinical outcome. ALCL-ALK− is generally responsive to doxorubicin-containing chemotherapy, but relapses are frequent. CHOP is the most commonly used regimen to treat systemic ALCL with complete remission rates of 56%, and a 10-year DFS of 28%. Encouraging results have been reported with more intensive chemotherapy regimens. The addition of etoposide improved outcome. Alemtuxumab-CHOP regimen was associated with excellent remission rate but increased toxicity. The role of high-dose chemotherapy supported by ASCT has not been investigated in a trial of exclusively ALCL patients. When used in first remission, it was associated with a 5-year PFS of 64%. High-dose chemotherapy with ASCT is the standard therapeutic option for patients with relapsed or refractory disease. The role of allogeneic transplantation in patients with relapsed/refractory ALCL remains to be defined but there are data to support the contention that a graft-versus-lymphoma effect does exist. Myeloablative conditioning has been associated with 5-year PFS and OS of 40% and 41%, respectively, but a 5-year TRM of 33% was reported. Allo-SCT can be an option for relapsed/refractory ALCL in younger patients, preferably in the setting of a clinical trial. Pralatrexate, anti-CD30 monoclonal antibodies, brentuximab vedotin (SGN-35) in particular, 131I-anti-CD45 radioantibody, yttrium-anti-CD25 radioimmunoconjugates, histone deacetylase inhibitors, bortezomib, gemcitabine, vorinostat, lenalidomide, and their combinations represent the most appealing chemotherapy and/or targeted agents to be investigated in future trials." @default.
• W2517435317 created "2016-09-16" @default.
• W2517435317 creator A5017873196 @default.
• W2517435317 creator A5036985315 @default.
• W2517435317 creator A5043985252 @default.
• W2517435317 creator A5050568632 @default.
• W2517435317 date "2013-02-01" @default.
• W2517435317 modified "2023-10-02" @default.
• W2517435317 title "Anaplastic large cell lymphoma, ALK-negative" @default.
• W2517435317 cites W150572272 @default.
• W2517435317 cites W1922967872 @default.
• W2517435317 cites W1963873790 @default.
• W2517435317 cites W1967803561 @default.
• W2517435317 cites W1969136385 @default.
• W2517435317 cites W1972258084 @default.
• W2517435317 cites W1983486168 @default.
• W2517435317 cites W1998063776 @default.
• W2517435317 cites W2008600357 @default.
• W2517435317 cites W2014665241 @default.
• W2517435317 cites W2026622976 @default.
• W2517435317 cites W2029853967 @default.
• W2517435317 cites W2033223017 @default.
• W2517435317 cites W2035920292 @default.
• W2517435317 cites W2045378618 @default.
• W2517435317 cites W2047758598 @default.
• W2517435317 cites W2049806545 @default.
• W2517435317 cites W2052578245 @default.
• W2517435317 cites W2058767673 @default.
• W2517435317 cites W2060499380 @default.
• W2517435317 cites W2060670573 @default.
• W2517435317 cites W2065817150 @default.
• W2517435317 cites W2074643584 @default.
• W2517435317 cites W2080329723 @default.
• W2517435317 cites W2087232492 @default.
• W2517435317 cites W2087516193 @default.
• W2517435317 cites W2093401714 @default.
• W2517435317 cites W2095783492 @default.
• W2517435317 cites W2097071314 @default.
• W2517435317 cites W2097339599 @default.
• W2517435317 cites W2108465006 @default.
• W2517435317 cites W2117152340 @default.
• W2517435317 cites W2120052745 @default.
• W2517435317 cites W2131064046 @default.
• W2517435317 cites W2133267160 @default.
• W2517435317 cites W2134210438 @default.
• W2517435317 cites W2142599682 @default.
• W2517435317 cites W2145164152 @default.
• W2517435317 cites W2147775411 @default.
• W2517435317 cites W2149566233 @default.
• W2517435317 cites W2150120498 @default.
• W2517435317 cites W2151523747 @default.
• W2517435317 cites W2151747638 @default.
• W2517435317 cites W2156517973 @default.
• W2517435317 cites W2161984323 @default.
• W2517435317 cites W2166766006 @default.
• W2517435317 cites W2169574298 @default.
• W2517435317 cites W2325145605 @default.
• W2517435317 cites W2409346720 @default.
• W2517435317 cites W2412720115 @default.
• W2517435317 cites W2473557619 @default.
• W2517435317 cites W2582242341 @default.
• W2517435317 cites W4234821789 @default.
• W2517435317 cites W88081109 @default.
• W2517435317 doi "https://doi.org/10.1016/j.critrevonc.2012.06.004" @default.
• W2517435317 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22789917" @default.
• W2517435317 hasPublicationYear "2013" @default.
• W2517435317 type Work @default.
• W2517435317 sameAs 2517435317 @default.
• W2517435317 citedByCount "121" @default.
• W2517435317 countsByYear W25174353172012 @default.
• W2517435317 countsByYear W25174353172013 @default.
• W2517435317 countsByYear W25174353172014 @default.
• W2517435317 countsByYear W25174353172015 @default.
• W2517435317 countsByYear W25174353172016 @default.
• W2517435317 countsByYear W25174353172017 @default.
• W2517435317 countsByYear W25174353172018 @default.
• W2517435317 countsByYear W25174353172019 @default.
• W2517435317 countsByYear W25174353172020 @default.
• W2517435317 countsByYear W25174353172021 @default.
• W2517435317 countsByYear W25174353172022 @default.
• W2517435317 countsByYear W25174353172023 @default.
• W2517435317 crossrefType "journal-article" @default.
• W2517435317 hasAuthorship W2517435317A5017873196 @default.
• W2517435317 hasAuthorship W2517435317A5036985315 @default.
• W2517435317 hasAuthorship W2517435317A5043985252 @default.
• W2517435317 hasAuthorship W2517435317A5050568632 @default.
• W2517435317 hasBestOaLocation W25174353171 @default.
• W2517435317 hasConcept C117643217 @default.
• W2517435317 hasConcept C121608353 @default.
• W2517435317 hasConcept C126322002 @default.
• W2517435317 hasConcept C142724271 @default.
• W2517435317 hasConcept C143998085 @default.
• W2517435317 hasConcept C2776232967 @default.
• W2517435317 hasConcept C2776256026 @default.
• W2517435317 hasConcept C2777872185 @default.
• W2517435317 hasConcept C2778911148 @default.
• W2517435317 hasConcept C2779338263 @default.
• W2517435317 hasConcept C2779714933 @default.

• next